Phenex Pharmaceuticals AG, of Ludwigshafen, Germany, began a Phase I trial of its candidate for non-alcoholic steatohepatitis, Px-102. The study will escalate through seven dose levels, and the first dose tested has produced no discomforts or adverse effects.